Dapagliflozin for heart function after Fontan procedure
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had the Fontan procedure for a single ventricle heart condition.
- You are at least 12 years old and weigh 30 kg (66 lbs) or more.
- You have not used any SGLT2 inhibitor (like dapagliflozin, empagliflozin) in the last 6 months.
- You do not have serious kidney disease, current infections, or diabetes that requires insulin.
- You are not pregnant or breastfeeding.
- You can do an exercise test on a bike or treadmill.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
This study tests how a medication called DAPA (an SGLT2 inhibitor) affects the body in people with heart failure (with or without type 2 diabetes), or in some people with type 2 diabetes only. It may help researchers understand who could benefit most and what changes happen in the heart, using specialized heart imaging.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial studies whether dapagliflozin (a heart-failure medicine) can improve anemia in people with heart failure. It may help explain why some patients feel better and how anemia changes when this medicine is used.
This study tests whether dapagliflozin (a medicine already approved for other heart conditions) can help protect kidney and heart function in people with very advanced heart failure who are waiting for a heart transplant. If you qualify, you'll help researchers learn if this drug offers extra benefits beyond standard care.
Hear when a new Fontan trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.